CYTOTOXICITY OF ANTHRACYCLINES - CORRELATION WITH CELLULAR UPTAKE, INTRACELLULAR-DISTRIBUTION AND DNA-BINDING

被引:19
作者
GIESELER, F [1 ]
BIERSACK, H [1 ]
MANDERSCHEID, J [1 ]
NUSSLER, V [1 ]
机构
[1] UNIV MUNICH,KLINIKUM GROSSHADERN,D-81377 MUNICH,GERMANY
关键词
ANTHRACYCLINES; TOPOISOMERASE II; DNA BINDING; CYTOTOXICITY;
D O I
10.1007/BF01757349
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to interact with topoisomerase II and induce genotoxicity, anthracyclines have to cross the outer cell membrane and the cytoplasm, enter the nucleus, and bind to the DNA. We incubated sensitive and resistant hematopoietic cells from cell lines and patient cells with daunorubicin, idarubicin, and its active derivative idarubicinol, extracted the anthracyclines from whole cells and nuclei, and determined their concentration fluorimetrically. Additionally, the DNA binding of the drugs was evaluated in the same cells by determining fluorescence resonance energy transfer between the anthracyclines and DNA-bound Hoechst dye 33342. We found a several thousand-fold accumulation of anthracyclines in sensitive and resistant hematopoietic cells; 30-60% of the drugs are found in the nucleus, resulting in 200- to 300-fold differences in concentration between the nucleus and outer fluids. A small proportion of the intracellular or intranuclear anthracyclines is bound to the DNA. The amount of DNA-bound anthracyclines correlates directly to cell death. It takes an additional 10 min for idarubicin and 30 min for daunorubicin to satisfy DNA binding sites after the drugs have arrived in the nucleus. The described methods provide the means to perform ex vivo studies on clinical material.
引用
收藏
页码:S13 / S17
页数:5
相关论文
共 16 条
[1]   INTERCALATION OF ANTHRACYCLINES INTO LIVING CELL-DNA ANALYZED BY FLOW-CYTOMETRY [J].
BELLOC, F ;
LACOMBE, F ;
DUMAIN, P ;
LOPEZ, F ;
BERNARD, P ;
BOISSEAU, MR ;
REIFERS, J .
CYTOMETRY, 1992, 13 (08) :880-885
[2]   COMPARISON OF INTRACELLULAR DRUG RETENTION, DNA DAMAGE AND CYTO-TOXICITY OF DERIVATIVES OF DOXORUBICIN AND DAUNORUBICIN IN A HUMAN-COLON ADENOCARCINOMA CELL-LINE (LOVO) [J].
BELVEDERE, G ;
SUARATO, A ;
GERONI, C ;
GIULIANI, FC ;
DINCALCI, M .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (21) :3713-3721
[3]   HPLC AND FLOW CYTOMETRIC ANALYSES OF UPTAKE OF ADRIAMYCIN AND MENOGARIL BY MONOLAYERS AND MULTICELL SPHEROIDS [J].
BICHAY, TJ ;
ADAMS, EG ;
INCH, WR ;
ADAMS, WJ ;
BREWER, JE ;
BHUYAN, BK .
SELECTIVE CANCER THERAPEUTICS, 1990, 6 (04) :153-166
[4]   SEQUENCE-SELECTIVE TOPOISOMERASE-II INHIBITION BY ANTHRACYCLINE DERIVATIVES IN SV40 DNA - RELATIONSHIP WITH DNA-BINDING AFFINITY AND CYTOTOXICITY [J].
CAPRANICO, G ;
ZUNINO, F ;
KOHN, KW ;
POMMIER, Y .
BIOCHEMISTRY, 1990, 29 (02) :562-569
[5]   QUANTIFICATION BY LASER SCAN MICROSCOPY OF INTRACELLULAR DOXORUBICIN DISTRIBUTION [J].
DELANGE, JHM ;
SCHIPPER, NW ;
SCHUURHUIS, GJ ;
TENKATE, TK ;
VANHEIJNINGEN, THM ;
PINEDO, HM ;
LANKELMA, J ;
BAAK, JPA .
CYTOMETRY, 1992, 13 (06) :571-576
[6]   DNA DAMAGE AND CYTOTOXICITY INDUCED BY METABOLITES OF ANTHRACYCLINE ANTIBIOTICS, DOXORUBICIN AND IDARUBICIN [J].
FERRAZZI, E ;
WOYNAROWSKI, JM ;
ARAKALI, A ;
BRENNER, DE ;
BEERMAN, TA .
CANCER COMMUNICATIONS, 1991, 3 (06) :173-180
[7]  
GIESELER F, 1992, HEMATOLOGY BLOOD TRA, V34, P44
[8]   ORAL IDARUBICIN - AN ANTHRACYCLINE DERIVATIVE WITH UNIQUE PROPERTIES [J].
GOEBEL, M .
ANNALS OF HEMATOLOGY, 1993, 66 (01) :33-43
[9]   IDARUBICIN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN THE CHEMOTHERAPY OF CANCER [J].
HOLLINGSHEAD, LM ;
FAULDS, D .
DRUGS, 1991, 42 (04) :690-719
[10]   ANTHRACYCLINES AND THEIR C-13 ALCOHOL METABOLITES - GROWTH-INHIBITION AND DNA DAMAGE FOLLOWING INCUBATION WITH HUMAN TUMOR-CELLS IN CULTURE [J].
KUFFEL, MJ ;
REID, JM ;
AMES, MM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (01) :51-57